自1864年以来,英国药典（BP）一直为配药材料和YY产品提供权威的官方标准的标准品，它为医药和保健产品管理机构作出很大的贡献，通过为保证药物质量制造公开有效的标准品来保护公众健康。
除了扩大专著量取得产品制定的许可证，公司还支持对于草药和补充药品领域的监管工作，
通过为传统草药产品、顺势疗法药品的存货和母酊剂提供新专著。BP也已开始提高未经许可药品的质量，为广泛使用的无证药物、未经授权的配方提供标准品连同更多的法律上和道德上的指导和这些产品的补充。
BP与欧洲药典的工作保持密切联系,将继续扮演在欧洲标准制定过程的重要角色，积极参与欧洲理事会药品质量和卫生保健的活动, 通过英国代表团影响欧洲药典委员会的决策。欧洲药典的文本和专著是BP的组成部分。
经过每年的不断更新,BP是WY可以向英国YY物质提供综合性标准品的。这对于所有参与医药研究、开发、制造、质量控制的个人和机构和分析都是很重要的。
自首次出版之后，BP的发展已经遍布全世界。现在五大洲中接近100个国家都在使用BP的产品，BP正在为的制药合规设立一系列的标准。英国周边的国家只有澳大利亚和加拿大这两个国家采用了BP的标准作为他们的国家标准。
Since 1864, the British Pharmacopoeia （BP） has been providing authoritative official standards for pharmaceutical substances ａnd medicinal products. It makes an important contribution to the role of the Medicines ａnd Healthcare products Regulatory Agency in protecting public health by setting publicly available standards for the quality of medicines.
In addition to expanding the numbers of monographs for licensed formulated products, it supports the regulatory work in the fields of herbal ａnd complementary medicines by providing new monographs for traditional herbal medicinal products ａnd for homoeopathic stocks ａnd mother tinctures. The BP has also begun to improve the control of the quality of unlicensed medicines by providing standards for extensively used unlicensed formulations together with further legal ａnd ethical guidance on the preparation ａnd supply of these products.
The British Pharmacopoeia maintains close ties with the work of the European Pharmacopoeia ａnd continues to play a significant role in the standard-setting process in Europe, participating in the activities of the European Directorate for the Quality of Medicines ａnd Healthcare, ａnd influencing the decisions of the European Pharmacopoeia Commission through the United Kingdom Delegation. The texts ａnd monographs of the European Pharmacopoeia form an integral part of the BP.
Annually updated, the British Pharmacopoeia is the only comprehensive collection of standards for UK medicinal substances. It is essential for all individuals ａnd organisations involved in pharmaceutical research, development, manufacture, quality control ａnd analysis.
Since its first publication the distribution of the British Pharmacopoeia has grown throughout the world. Now used in approaching 100 countries with exposure in most continents of the world, the BP is setting the standard for pharmaceutical compliance across the globe. Australia ａnd Canada are just two of the countries that have adopted the BP as their national standard alongside the UK.
